A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Solowij, Nadia ^a   Broyd, Samantha J ^a   van Hell, Hendrika H ^a   Hazekamp, Arno ^b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cannabidiol (CBD); Cannabinoids; Intrapulmonary Administration; Vaporisation; 9 Tetrahydrocannabinol (THC)

Indexed keywords

CANNABIDIOL; DRONABINOL;

ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PURIFICATION; HUMAN; LIMIT OF QUANTITATION; LOW DRUG DOSE; MONOTHERAPY; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; VAPORIZATION; VAPORIZER; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; CANNABIDIOL; DRONABINOL; HUMANS;

EID: 84964315511     PISSN: None     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-58     Document Type: Article

References (24)

1. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH: The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572
2. Zuardi AW: Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatria 2008, 30:271-280
3. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94
4. Morgan CJ, Curran HV: Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008, 192:306-307
5. Morgan CJ, Schafer G, Freeman TP, Curran HV: Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010, 197:285-290
6. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O'Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK: Opposite effects of δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774
7. Schoedel KA, Harrison SJ: Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Curr Pharm Des 2012, 18:5008-5014
8. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M: Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983, 34:352-363
9. Grotenhermen F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinetics 2003, 42:327-360
10. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L: Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986, 38:21-43
11. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R: Evaluation of a vaporizing device (Volcano°) for the pulmonary delivery of tetrahydrocannabinol. J Pharm Sci 2006, 95:1308-1317
12. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JCME, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JMA: Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacology 2008, 22:707-716
13. 9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766
14. van Hell HH, Bossong MG, Jager G, Kahn RS, Ramsey NF: Pharmacological imaging of the cannabinoid system (PhICS): towards understanding the role of the brain endocannabinoid system in human cognition. Int J Methods Psychiatr Res 2011, 20:10-27
15. Hazekamp A, Simons R, Peltenburg-Looman A, Sengers M, Van Zweden R, Verpoorte R: Preparative isolation of cannabinoids from Cannabis sativa by centrifugal partition chromatography. J Liquid Chromat Rel Technol 2004, 27:2421-2439
16. Hazekamp A, Choi YH, Verpoorte R: Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chem Pharm Bull 2004, 52:718-721
17. Romano LL, Hazekamp A: Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013, 1:1-11
18. Solowij N: Vulnerability markers in the association between cannabis and schizophrenia: a randomised controlled trial of acute cannabinoid administration. Current Controlled Trials 2012, 5:5. http://www.controlledtrials. com/ISRCTN24109245
19. Potter DJ, Clark P, Brown MB: Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008, 53:90-94
20. Swift W, Wong A, Li KM, Arnold JC, McGregor IS: Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS One 2013, 8:e70052
21. Bergamaschi MM, Costa Queiroz RH, Nisihara Chagas MH, de Gomes Oliveira DC, de Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JAS: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226
22. 9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 2011, 218:443-457
23. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, Martin BR: Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 2006, 186:226-234
24. Zuardi AW, Hallak JE, Crippa JA: Interaction between cannabidiol (CBD) and δ(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 2012, 219:247-249